Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials

IF 4.7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Obesity Pub Date : 2025-01-05 DOI:10.1002/oby.24202

Beverly G. Tchang, Michael G. Knight, Kasper Adelborg, Jennifer N. Clements, Aske Thorn Iversen, Andrea Traina

{"title":"Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials","authors":"Beverly G. Tchang, Michael G. Knight, Kasper Adelborg, Jennifer N. Clements, Aske Thorn Iversen, Andrea Traina","doi":"10.1002/oby.24202","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The objective of this study was to assess antihypertensive and lipid-lowering treatment changes in participants receiving semaglutide 2.4 mg versus placebo across pooled populations from five Semaglutide Treatment Effect in People with Obesity (STEP) trials.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Efficacy and safety of semaglutide 2.4 mg were evaluated in the STEP clinical trials. In this post hoc analysis, STEP 1, 3, 6, and 8 (which included people with overweight or obesity) and, separately, STEP 2 and 6 (which included people with overweight or obesity and type 2 diabetes) were pooled for analysis. Changes in antihypertensive or lipid-lowering treatment intensity from randomization to end of treatment were evaluated.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In both pooled samples, a higher proportion of participants in the semaglutide 2.4 mg group versus placebo underwent antihypertensive or lipid-lowering treatment intensity reduction by end of treatment. A smaller proportion underwent antihypertensive or lipid-lowering treatment intensification by end of treatment in the semaglutide 2.4 mg group of both samples versus placebo. In participants receiving antihypertensive or lipid-lowering medications in both samples, greater numeric reductions in body weight were observed in the semaglutide 2.4 mg group versus placebo.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>These results support a relationship between semaglutide 2.4 mg treatment of overweight and obesity and reduced need for antihypertensive and lipid-lowering treatment, facilitating treatment intensity reduction/discontinuation and abating treatment intensification.</p>\n \n <div>\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </div>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 2","pages":"267-277"},"PeriodicalIF":4.7000,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774009/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.24202","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The objective of this study was to assess antihypertensive and lipid-lowering treatment changes in participants receiving semaglutide 2.4 mg versus placebo across pooled populations from five Semaglutide Treatment Effect in People with Obesity (STEP) trials.

Methods

Efficacy and safety of semaglutide 2.4 mg were evaluated in the STEP clinical trials. In this post hoc analysis, STEP 1, 3, 6, and 8 (which included people with overweight or obesity) and, separately, STEP 2 and 6 (which included people with overweight or obesity and type 2 diabetes) were pooled for analysis. Changes in antihypertensive or lipid-lowering treatment intensity from randomization to end of treatment were evaluated.

Results

In both pooled samples, a higher proportion of participants in the semaglutide 2.4 mg group versus placebo underwent antihypertensive or lipid-lowering treatment intensity reduction by end of treatment. A smaller proportion underwent antihypertensive or lipid-lowering treatment intensification by end of treatment in the semaglutide 2.4 mg group of both samples versus placebo. In participants receiving antihypertensive or lipid-lowering medications in both samples, greater numeric reductions in body weight were observed in the semaglutide 2.4 mg group versus placebo.

Conclusions

These results support a relationship between semaglutide 2.4 mg treatment of overweight and obesity and reduced need for antihypertensive and lipid-lowering treatment, facilitating treatment intensity reduction/discontinuation and abating treatment intensification.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

5项随机对照STEP试验中，西马鲁肽2.4 mg对降压降脂治疗的影响。

目的：本研究的目的是评估来自5项塞马鲁肽治疗肥胖症（STEP）试验的合并人群中接受塞马鲁肽2.4 mg与安慰剂治疗的参与者的降压和降脂治疗变化。方法：在STEP临床试验中评价西马鲁肽2.4 mg的疗效和安全性。在这个事后分析中，步骤1、3、6和8（包括超重或肥胖的人）以及步骤2和6（包括超重或肥胖和2型糖尿病的人）被合并进行分析。评估从随机分组到治疗结束的降压或降脂治疗强度的变化。结果：在这两个合并的样本中，在治疗结束时，与安慰剂组相比，semaglutide 2.4 mg组的参与者接受降压或降脂治疗强度降低的比例更高。在治疗结束时，与安慰剂组相比，使用semaglutide 2.4 mg组接受降压或降脂治疗的比例更小。在接受降压或降脂药物治疗的两组受试者中，与安慰剂组相比，semaglutide 2.4 mg组的体重下降幅度更大。结论：这些结果支持西马鲁肽2.4 mg治疗超重和肥胖与降低降压和降脂治疗需求之间的关系，促进治疗强度的降低/停止和治疗强度的减弱。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Obesity 医学-内分泌学与代谢

CiteScore

11.70

自引率

1.40%

发文量

261

审稿时长

2-4 weeks

期刊介绍： Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.